within Pharmacolibrary.Drugs.ATC.C;

model C08CX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.035,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015000000000000001,
    Tlag           = 60,            
    Vdp             = 0.214,
    k12             = 90,
    k21             = 90
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C08CX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mibefradil is a calcium channel blocker formerly used as an antihypertensive and antianginal agent. It was primarily used for the treatment of hypertension and chronic stable angina pectoris. Due to serious drug interactions, mibefradil was withdrawn from the market in 1998 and is not used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from studies in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Welker, HA, et al., &amp; Bullingham, R (1998). Clinical pharmacokinetics of mibefradil. <i>Clinical pharmacokinetics</i> 35(6) 405–423. DOI:<a href=\"https://doi.org/10.2165/00003088-199835060-00001\">10.2165/00003088-199835060-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9884814/\">https://pubmed.ncbi.nlm.nih.gov/9884814</a></p></li><li><p>Skerjanec, A, et al., &amp; Tam, YK (1996). Nonlinear pharmacokinetics of mibefradil in the dog. <i>Journal of pharmaceutical sciences</i> 85(2) 189–192. DOI:<a href=\"https://doi.org/10.1021/js9501775\">10.1021/js9501775</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8683447/\">https://pubmed.ncbi.nlm.nih.gov/8683447</a></p></li><li><p>Veronese, ML, et al., &amp; Greenberg, HE (2003). Effect of mibefradil on CYP3A4 in vivo. <i>Journal of clinical pharmacology</i> 43(10) 1091–1100. DOI:<a href=\"https://doi.org/10.1177/0091270003256687\">10.1177/0091270003256687</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14517191/\">https://pubmed.ncbi.nlm.nih.gov/14517191</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C08CX01;
